intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Company profile
Ticker
NTLA
Exchange
Website
CEO
John Leonard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Intellia Securities Corp. ...
NTLA stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
26 Feb 24
424B5
Prospectus supplement for primary offering
23 Feb 24
8-K
Amendment No. 1 to the Open Market Sale Agreementsm
23 Feb 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
22 Feb 24
8-K
Regulation FD Disclosure
1 Feb 24
8-K
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
4 Jan 24
8-K
Departure of Directors or Certain Officers
6 Dec 23
S-3ASR
Automatic shelf registration
24 Nov 23
Transcripts
NTLA
Earnings call transcript
2023 Q4
22 Feb 24
NTLA
Earnings call transcript
2023 Q3
9 Nov 23
NTLA
Earnings call transcript
2023 Q2
3 Aug 23
NTLA
Earnings call transcript
2023 Q2
3 Aug 23
NTLA
Earnings call transcript
2023 Q1
4 May 23
NTLA
Earnings call transcript
2022 Q4
23 Feb 23
NTLA
Earnings call transcript
2022 Q3
3 Nov 22
NTLA
Earnings call transcript
2022 Q2
4 Aug 22
NTLA
Earnings call transcript
2022 Q1
5 May 22
NTLA
Earnings call transcript
2021 Q4
24 Feb 22
Latest ownership filings
4
Laura Sepp-Lorenzino
5 Mar 24
4
JAMES BASTA
5 Mar 24
4
Derek Hicks
5 Mar 24
4
Eliana Clark
5 Mar 24
4
JOHN M LEONARD
5 Mar 24
4
David Lebwohl
5 Mar 24
4
Glenn Goddard
5 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
STATE STREET CORP
24 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 180.98 mm | 180.98 mm | 180.98 mm | 180.98 mm | 180.98 mm | 180.98 mm |
Cash burn (monthly) | 926.33 k | (no burn) | 43.70 mm | 40.46 mm | 33.79 mm | 32.58 mm |
Cash used (since last report) | 5.21 mm | n/a | 245.78 mm | 227.53 mm | 190.05 mm | 183.20 mm |
Cash remaining | 175.77 mm | n/a | -64.79 mm | -46.54 mm | -9.07 mm | -2.21 mm |
Runway (months of cash) | 189.8 | n/a | -1.5 | -1.2 | -0.3 | -0.1 |
Institutional ownership, Q3 2023
88.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 275 |
Opened positions | 33 |
Closed positions | 41 |
Increased positions | 117 |
Reduced positions | 63 |
13F shares | Current |
---|---|
Total value | 2.50 tn |
Total shares | 85.18 mm |
Total puts | 346.20 k |
Total calls | 352.70 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 9.95 mm | $314.58 bn |
Vanguard | 8.19 mm | $259.03 bn |
BLK Blackrock | 8.13 mm | $257.16 bn |
STT State Street | 3.73 mm | $118.04 bn |
REGN Regeneron Pharmaceuticals | 3.70 mm | $437.84 mm |
CMTDF Sumitomo Mitsui Trust | 3.52 mm | $111.31 bn |
Nikko Asset Management Americas | 3.52 mm | $111.17 bn |
MS Morgan Stanley | 3.09 mm | $97.74 bn |
Wellington Management | 2.65 mm | $83.86 bn |
Novartis Institutes for BioMedical Research | 2.18 mm | $157.97 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Basta James | Common Stock | Sell | Dispose S | No | No | 32.99 | 2,297 | 75.78 k | 81,571 |
4 Mar 24 | Eliana Clark | Common Stock | Sell | Dispose S | No | No | 32.99 | 605 | 19.96 k | 71,470 |
1 Mar 24 | Laura Sepp-Lorenzino | Common Stock | Grant | Acquire A | No | No | 0 | 37,966 | 0.00 | 81,893 |
1 Mar 24 | Laura Sepp-Lorenzino | Stock Option Common Stock | Grant | Acquire A | No | No | 32.66 | 54,794 | 1.79 mm | 54,794 |
1 Mar 24 | Basta James | Common Stock | Grant | Acquire A | No | No | 0 | 32,394 | 0.00 | 83,868 |
1 Mar 24 | Basta James | Stock Option Common Stock | Grant | Acquire A | No | No | 32.66 | 46,752 | 1.53 mm | 46,752 |
1 Mar 24 | Derek Hicks | Common Stock | Grant | Acquire A | No | No | 0 | 29,393 | 0.00 | 66,380 |
1 Mar 24 | Derek Hicks | Stock Option Common Stock | Grant | Acquire A | No | No | 32.66 | 42,421 | 1.39 mm | 42,421 |
1 Mar 24 | Eliana Clark | Common Stock | Grant | Acquire A | No | No | 0 | 31,230 | 0.00 | 72,075 |
1 Mar 24 | Eliana Clark | Stock Option Common Stock | Grant | Acquire A | No | No | 32.66 | 45,072 | 1.47 mm | 45,072 |
News
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
18 Mar 24
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
26 Feb 24
Goldman Sachs Downgrades Intellia Therapeutics to Neutral, Announces $32 Price Target
23 Feb 24
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $73
23 Feb 24
Intellia Therapeutics Q4 EPS $(1.46) Misses $(1.45) Estimate, Sales $(1.92M) May Not Be Comparable To $12.83M Estimate
22 Feb 24
Press releases
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
18 Mar 24
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
22 Feb 24
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
15 Feb 24
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
14 Feb 24
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
31 Jan 24